Aehr Test Systems, Inc.
AEHRAehr Test Systems, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +181.3% in a year while annual EPS moved −111.6% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (53 weeks in) while the P/E sits at the 59th percentile of its own 4-year range. Underneath, the last four quarters read mixed, and 20% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Aehr Test Systems, Inc. trades at $84.3, in a confirmed uptrend and 53 weeks into that stage. That is +29.4% against its own 200-day average. It sits at 56% of a 52-week range of $20 to $134. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a confirmed uptrend — week 53 of stage 2. At $84.3 it trades +29.4% versus its 200-day average and sits at 56% of its 52-week range ($20–$134).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +5,301% while the S&P 500 moved +255% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-08-21) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Aehr Test Systems, Inc. trades at 39.8× P/E, mid-range by its own standards (59th percentile). Its long-run median P/E is 33.2×, measured across 3.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 39.8× is mid-range by its own standards (59th percentile), against a long-run median of 33.2× measured over 3.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −111.6% against a +181.3% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +21.4%/yr price move, ~+33.2%/yr came from earnings growth and ~−11.8 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Aehr Test Systems, Inc. reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −33.3% latest against +33.3% at its 12-quarter best), ROCE holding at 0.0%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −14.3% | +6.3% | — | — |
| Stock price | +181.3% | +21.4% | +50.0% | +42.7% |
4-Factor Sector Score
47.3/100 — rank 14 of 29 in Semiconductor Equipment & Materials · 56% evidence confidence
Aehr Test Systems, Inc. scores 47.3 out of 100 against the 29 companies it is compared with in Semiconductor Equipment & Materials, ranking 14. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 15.9 + 5 + 11.5 + 14.9 = 47.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Aehr Test Systems, Inc. reported $0.0 B of revenue in the Feb 26 quarter, −50.0% year on year. Over 4 years it has compounded at 31.6% a year. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.0 B.
FY25 revenue came in at $0.1 B (−14.3% on the year), capping 4 years at 31.6% compound. The latest quarter (Feb 26) printed $0.0 B, −50.0% year on year.
Pace check: the last four quarters averaged −25.0% growth against the decade's 31.6% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −33.3% over the last 4 quarters against −24.4%/yr over the last 8 — rolling over; TTM profit −100.0% vs −100.0%/yr — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Aehr Test Systems, Inc.'s operating margin is 0.0% in the Feb 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −16.7% to 20.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 0.0%, +0.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −16.7%–20.0%.
Why the margin moved: operating margin went +0.0 pp year on year while gross margin went −50.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Aehr Test Systems, Inc. earned $0.0 B of net profit in the Feb 26 quarter. Full-year FY25 profit was $0.0 B. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Feb 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $0.0 B (−100.0%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 20% of Aehr Test Systems, Inc.'s reported profit arrived as operating cash — a gap worth watching. In FY25 that was $−0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $−0.0 B was left as free cash.
FY25: operating cash of $−0.0 B against reported profit of $0.0 B, leaving free cash of $−0.0 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 20% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Aehr Test Systems, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Aehr Test Systems, Inc. earns a ROE of 0% in FY25. Return on invested capital clears the cost of that capital by −33.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 0.0% net margin on 0.40× asset turns.
FY25 ROE is 0%.
🚨 Why the return is what it is — the wiring (FY25): 0.0% net margin × 0.40× asset turns × 1.25× balance-sheet leverage ≈ 0.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: −12.6% − 21.0% = a −33.6 pp spread. The 21.0% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
Aehr Test Systems, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Aehr Test Systems, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Aehr Test Systems, Inc. carries total debt of $0.0 B against shareholder equity of $0.2 B as of May 26, a debt-to-equity of 0.05 — effectively unlevered. On the annual view that ratio went from 0.00 in FY21 to 0.05 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
May 26: total debt of $0.0 B against shareholder equity of $0.2 B — a debt-to-equity of 0.05. On the annual view, debt-to-equity went from 0.00 (FY21) to 0.05 (FY26). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
13.9% of Aehr Test Systems, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 1.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 13.9% of the float is sold short, and at typical trading volumes it would take about 1.8 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Aehr Test Systems, Inc.: the Z-score reads 23.98. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 23.98 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 23.98.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Teradyne, Inc.TER | 78.1/100Favorable setup81% evidence | ASLEEP | 30.9/35 Revenue 57.8% · PAT 100% · OPM change 19 pp 83% evidence | 17.4/25 ROCE 12.7% · OPM 32.9% 76% evidence | 12.2/20 P/E 59.9× · PEG 1.04 65% evidence | 17.6/20 RS sector 5.1% · RS bench 10.8% · 1Y 184.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 30.9 + 17.4 + 12.2 + 17.6 = 78.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Lam Research CorporationLRCX | 71.5/100Favorable setup81% evidence | ASLEEP | 28.8/35 Revenue 26% · PAT 35.6% · OPM change 3.7 pp 83% evidence | 21.4/25 ROCE 46.6% · OPM 37.4% 76% evidence | 9.0/20 P/E 65.3× · PEG 1.68 65% evidence | 12.3/20 RS sector -1.8% · RS bench 4.7% · 1Y 112.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 28.8 + 21.4 + 9 + 12.3 = 71.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Applied Materials, Inc.AMAT | 62.6/100Mixed-positive evidence85% evidence | FADING | 19.2/35 Revenue 7.8% · PAT 35.6% · OPM change 3.1 pp 95% evidence | 20.4/25 ROCE 29% · OPM 33.7% 76% evidence | 11.8/20 P/E 45.9× · PEG 1.21 65% evidence | 11.2/20 RS sector -2.1% · RS bench 3.9% · 1Y 118.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 20.4 + 11.8 + 11.2 = 62.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4ASML Holding N.V.ASML | 62.1/100Mixed-positive evidence81% evidence | FADING | 20.9/35 Revenue 9.8% · PAT 13% · OPM change 2.5 pp 83% evidence | 21.1/25 ROCE 44.6% · OPM 37.1% 76% evidence | 5.6/20 P/E 57× · PEG 3.89 65% evidence | 14.5/20 RS sector -2.5% · RS bench 7% · 1Y 71.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 21.1 + 5.6 + 14.5 = 62.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 5FormFactor, Inc.FORM | 57.0/100Thin evidence · provisional56% evidence | ASLEEP | 21.6/35 Revenue — · PAT — · OPM change 5.5 pp 39% evidence | 12.4/25 ROCE 5.2% · OPM 7.4% 76% evidence | 9.0/20 P/E 89.5× · PEG — 15% evidence | 14.0/20 RS sector 2.7% · RS bench 6.5% · 1Y 197.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 12.4 + 9 + 14 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Kulicke and Soffa Industries, Inc.KLIC | 55.2/100Thin evidence · provisional56% evidence | ASLEEP | 22.2/35 Revenue — · PAT — · OPM change 20 pp 39% evidence | 12.2/25 ROCE 4% · OPM 15.9% 76% evidence | 9.7/20 P/E 61.6× · PEG — 15% evidence | 11.1/20 RS sector -1.1% · RS bench 3.4% · 1Y 89.4%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 12.2 + 9.7 + 11.1 = 55.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Cohu, Inc.COHU | 53.2/100Thin evidence · provisional56% evidence | FADING | 19.7/35 Revenue — · PAT — · OPM change 19.3 pp 39% evidence | 5.4/25 ROCE 0% · OPM -8.9% 76% evidence | 9.8/20 P/E 60× · PEG — 15% evidence | 18.3/20 RS sector 22.4% · RS bench 28% · 1Y 126.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 5.4 + 9.8 + 18.3 = 53.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8ACM Research, Inc.ACMR | 52.3/100Mixed-positive evidence66% evidence | FADING | 17.1/35 Revenue 19.7% · PAT -9% · OPM change 0.6 pp 53% evidence | 11.8/25 ROCE 2% · OPM 15.6% 57% evidence | 15.0/20 P/E 30× · PEG 0.75 65% evidence | 8.4/20 RS sector -2.6% · RS bench 3.5% · 1Y 80.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 11.8 + 15 + 8.4 = 52.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9KLA CorporationKLAC | 51.8/100Mixed-positive evidence81% evidence | ASLEEP | 18.2/35 Revenue 11.7% · PAT 18.9% · OPM change -0.1 pp 83% evidence | 21.0/25 ROCE 41.5% · OPM 42.5% 76% evidence | 4.2/20 P/E 81.6× · PEG 4 65% evidence | 8.4/20 RS sector -10.2% · RS bench -2.6% · 1Y 60.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 21 + 4.2 + 8.4 = 51.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 10Photronics, Inc.PLAB | 50.9/100Mixed-positive evidence81% evidence | ASLEEP | 14.0/35 Revenue 0.5% · PAT 24.1% · OPM change -6.3 pp 83% evidence | 13.6/25 ROCE 2.6% · OPM 20.1% 76% evidence | 16.3/20 P/E 18.2× · PEG 0.43 65% evidence | 7.0/20 RS sector -29.2% · RS bench -21.4% · 1Y 11.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 13.6 + 16.3 + 7 = 50.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11AXT, Inc.AXTI | 50.7/100Thin evidence · provisional56% evidence | ASLEEP | 21.3/35 Revenue — · PAT — · OPM change 47.2 pp 39% evidence | 7.0/25 ROCE 1.7% · OPM -5.9% 76% evidence | 8.5/20 P/E 3604× · PEG — 15% evidence | 13.9/20 RS sector 39.2% · RS bench 28.9% · 1Y 1381.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 7 + 8.5 + 13.9 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Qnity Electronics, Inc.Q | 49.9/100Thin evidence · provisional51% evidence | ASLEEP | 15.2/35 Revenue 14.8% · PAT -23.6% · OPM change -1.7 pp 83% evidence | 14.5/25 ROCE 4.3% · OPM 19.3% 76% evidence | 10.2/20 P/E 58.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 12 weeks ahead 0% evidence |
| Exact sum: 15.2 + 14.5 + 10.2 + 10 = 49.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Entegris, Inc.ENTG | 49.1/100Mixed-negative evidence81% evidence | ASLEEP | 16.4/35 Revenue 3.2% · PAT 3.4% · OPM change 4.2 pp 83% evidence | 14.0/25 ROCE 7.1% · OPM 19.3% 76% evidence | 7.6/20 P/E 80.6× · PEG 1.94 65% evidence | 11.1/20 RS sector -7% · RS bench 1.7% · 1Y 39.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 14 + 7.6 + 11.1 = 49.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Aehr Test Systems, Inc.this pageAEHR | 47.3/100Thin evidence · provisional56% evidence | ASLEEP | 15.9/35 Revenue — · PAT — · OPM change -34.9 pp 39% evidence | 5.0/25 ROCE -0.7% · OPM -41% 76% evidence | 11.5/20 P/E 12.4× · PEG — 15% evidence | 14.9/20 RS sector 43.4% · RS bench 41% · 1Y 181.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 5 + 11.5 + 14.9 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Camtek Ltd.CAMT | 46.3/100Mixed-negative evidence66% evidence | ASLEEP | 12.9/35 Revenue 10.6% · PAT -61.7% · OPM change -5.2 pp 53% evidence | 13.1/25 ROCE 2.7% · OPM 22.4% 57% evidence | 12.2/20 P/E 174.3× · PEG 0.8 65% evidence | 8.1/20 RS sector -18.9% · RS bench -10.3% · 1Y 42%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 13.1 + 12.2 + 8.1 = 46.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Amkor Technology, Inc.AMKR | 46.1/100Thin evidence · provisional56% evidence | ASLEEP | 20.2/35 Revenue — · PAT — · OPM change 3.6 pp 39% evidence | 12.2/25 ROCE 3% · OPM 6% 76% evidence | 10.8/20 P/E 38.7× · PEG — 15% evidence | 2.9/20 RS sector -21.2% · RS bench -15.5% · 1Y 63.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 12.2 + 10.8 + 2.9 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Nova Ltd.NVMI | 45.5/100Mixed-negative evidence66% evidence | ASLEEP | 19.5/35 Revenue 21.4% · PAT 24.6% · OPM change 0.5 pp 53% evidence | 14.7/25 ROCE 5.6% · OPM 30.1% 57% evidence | 7.0/20 P/E 54.1× · PEG 2.56 65% evidence | 4.3/20 RS sector -30.8% · RS bench -23.3% · 1Y 9.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 14.7 + 7 + 4.3 = 45.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Ultra Clean Holdings, Inc.UCTT | 45.3/100Thin evidence · provisional51% evidence | ASLEEP | 14.6/35 Revenue -3.2% · PAT -574.4% · OPM change -0.4 pp 40% evidence | 8.1/25 ROCE 0.7% · OPM 2.1% 57% evidence | 10.9/20 P/E 35.5× · PEG — 15% evidence | 11.7/20 RS sector 3.6% · RS bench 4% · 1Y 140.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 8.1 + 10.9 + 11.7 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Ichor Holdings, Ltd.ICHR | 43.9/100Thin evidence · provisional51% evidence | ASLEEP | 16.6/35 Revenue 7.6% · PAT — · OPM change 1.3 pp 40% evidence | 7.5/25 ROCE 0.2% · OPM 0.8% 57% evidence | 10.5/20 P/E 48.1× · PEG — 15% evidence | 9.3/20 RS sector 2.1% · RS bench 0.5% · 1Y 179%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 7.5 + 10.5 + 9.3 = 43.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Ambarella, Inc.AMBA | 42.3/100Mixed-negative evidence61% evidence | BASING | 21.5/35 Revenue 27.8% · PAT — · OPM change 10.8 pp 62% evidence | 3.5/25 ROCE -3.2% · OPM -19.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.3/20 RS sector -30.5% · RS bench -17.3% · 1Y -24.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 3.5 + 10 + 7.3 = 42.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21IPG Photonics CorporationIPGP | 42.2/100Mixed-negative evidence61% evidence | BASING | 15.5/35 Revenue 9.2% · PAT — · OPM change -3.7 pp 40% evidence | 8.2/25 ROCE -0.4% · OPM -2.9% 57% evidence | 13.2/20 P/E 166.1× · PEG 0.67 65% evidence | 5.3/20 RS sector -34.7% · RS bench -26.6% · 1Y -5.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 8.2 + 13.2 + 5.3 = 42.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22Axcelis Technologies, Inc.ACLS | 38.6/100Mixed-negative evidence66% evidence | ASLEEP | 11.1/35 Revenue -11.8% · PAT -44.1% · OPM change -11.1 pp 53% evidence | 10.4/25 ROCE 0.7% · OPM 4% 57% evidence | 12.8/20 P/E 29× · PEG 1.16 65% evidence | 4.3/20 RS sector -18.8% · RS bench -11.8% · 1Y 8.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 11.1 + 10.4 + 12.8 + 4.3 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Veeco Instruments Inc.VECO | 37.3/100Mixed-negative evidence66% evidence | ASLEEP | 10.6/35 Revenue -7.8% · PAT -64.1% · OPM change -10.2 pp 53% evidence | 8.5/25 ROCE -0.2% · OPM -1.7% 57% evidence | 13.8/20 P/E 89.1× · PEG 0.65 65% evidence | 4.4/20 RS sector -12.6% · RS bench -6.5% · 1Y 43.7%3 of 12 weeks ahead 100% evidence |
| Exact sum: 10.6 + 8.5 + 13.8 + 4.4 = 37.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24Trio-Tech InternationalTRT | 53.9/100Thin evidence · provisional14% evidence | 17.5/35 Revenue — · PAT — · OPM change — 0% evidence | 12.5/25 ROCE — · OPM — 0% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.9/20 RS sector 0.1% · RS bench 43.9% · 1Y 259.6%2 of 2 weeks ahead to 2026-07-10 70% evidence | |
| Exact sum: 17.5 + 12.5 + 10 + 13.9 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Onto Innovation Inc.ONTO | 46.5/100Thin evidence · provisional46% evidence | FADING | 14.7/35 Revenue — · PAT — · OPM change -18.5 pp 24% evidence | 10.5/25 ROCE 0.7% · OPM 5.2% 57% evidence | 10.1/20 P/E 59.7× · PEG — 15% evidence | 11.2/20 RS sector -3.7% · RS bench 2.6% · 1Y 98.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 10.5 + 10.1 + 11.2 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Amtech Systems, Inc.ASYS | 45.2/100Thin evidence · provisional45% evidence | ASLEEP | 19.4/35 Revenue -13.2% · PAT — · OPM change 211.5 pp 40% evidence | 9.9/25 ROCE 2.5% · OPM 8.8% 57% evidence | 9.5/20 P/E 68.7× · PEG — 15% evidence | 6.4/20 RS sector -13.2% · RS bench -7.3% · 1Y 53.2%2 of 12 weeks ahead 70% evidence |
| Exact sum: 19.4 + 9.9 + 9.5 + 6.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27InTest CorporationINTT | 41.4/100Thin evidence · provisional45% evidence | ASLEEP | 18.6/35 Revenue -5.5% · PAT — · OPM change 13.6 pp 40% evidence | 9.2/25 ROCE 0.8% · OPM 2.8% 57% evidence | 8.6/20 P/E 341.3× · PEG — 15% evidence | 5.0/20 RS sector -21.6% · RS bench -16.5% · 1Y 35.9%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.6 + 9.2 + 8.6 + 5 = 41.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Atomera IncorporatedATOM | 41.2/100Thin evidence · provisional34% evidence | ASLEEP | 20.1/35 Revenue — · PAT — · OPM change 79084.1 pp 24% evidence | 6.8/25 ROCE -19.5% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.3/20 RS sector -29% · RS bench -26.3% · 1Y 3.2%2 of 12 weeks ahead 70% evidence |
| Exact sum: 20.1 + 6.8 + 10 + 4.3 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Daqo New Energy Corp.DQ | 33.0/100Thin evidence · provisional45% evidence | BASING | 12.2/35 Revenue -22.8% · PAT — · OPM change -472.4 pp 40% evidence | 6.4/25 ROCE -2.6% · OPM -564.4% 57% evidence | 11.4/20 P/E 12.5× · PEG — 15% evidence | 3.0/20 RS sector -62% · RS bench -51.9% · 1Y -58.4%0 of 12 weeks ahead 70% evidence |
| Exact sum: 12.2 + 6.4 + 11.4 + 3 = 33 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Aehr Test Systems, Inc.'s stock price today?
Aehr Test Systems, Inc. trades at $84.3, +181.3% over the past year. The company is valued at $3.0 B. The stock sits at 56% of its 52-week range of $20–$134, +29.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 53 weeks in. — as of 17 September 2026.
What were Aehr Test Systems, Inc.'s latest quarterly results?
Aehr Test Systems, Inc. reported revenue of $0.0 B and net profit of $0.0 B for the Feb 26 quarter. The operating margin was 0.0%, 0.0 pp higher than a year earlier. — as of 17 September 2026.
What is Aehr Test Systems, Inc.'s revenue?
Aehr Test Systems, Inc. reported revenue of $0.0 B in the Feb 26 quarter, −50.0% year on year. For the full FY25 fiscal year, revenue was $0.1 B (−14.3%). Over the last 4 years revenue compounded at 31.6% a year. — as of 17 September 2026.
What is Aehr Test Systems, Inc.'s profit?
Aehr Test Systems, Inc. earned $0.0 B of net profit in the Feb 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran 0.0% in the latest quarter. — as of 17 September 2026.
What is Aehr Test Systems, Inc.'s market cap?
Aehr Test Systems, Inc.'s market capitalisation is $3.0 B at a stock price of $84.3. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Aehr Test Systems, Inc.'s P/E ratio?
Aehr Test Systems, Inc. trades at a P/E of 39.8×, at the 59th percentile of its own 4-year range, against a long-run median of 33.2×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Aehr Test Systems, Inc. pay a dividend?
No — Aehr Test Systems, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is Aehr Test Systems, Inc. overvalued?
On its own history, Aehr Test Systems, Inc. looks mid-range: its P/E of 39.8× sits at the 59th percentile of its 4-year range (long-run median 33.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
How is Aehr Test Systems, Inc. performing?
Aehr Test Systems, Inc. is in a confirmed uptrend, 53 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Aehr Test Systems, Inc. in?
Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −33.3% latest against +33.3% at its 12-quarter best), ROCE holding at 0.0%. The read comes from the last 12 quarters of growth (revenue growth −33.3% latest, profit growth −100.0% latest, eps growth −148.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Aehr Test Systems, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 53 of stage 2), trading +29.4% versus its 200-day average and at 56% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Aehr Test Systems, Inc. beating the market?
Not lately — on a trailing-13-week view Aehr Test Systems, Inc. is currently behind the S&P 500 (4 weeks and counting; last ahead the week of 2026-08-21), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +5,301% against the S&P 500's +255% — ahead of the index over the full window. — as of 17 September 2026.
Will Aehr Test Systems, Inc.'s stock price go up?
This page publishes no price forecast for Aehr Test Systems, Inc. What it measures instead: the stock price is $84.3, the price is in a confirmed uptrend 53 weeks in. Its P/E of 39.8× sits at the 59th percentile of its own 4-year range. — as of 17 September 2026.
Is the market betting against Aehr Test Systems, Inc.?
Yes — short interest is 13.9% of Aehr Test Systems, Inc.'s tradable float, about 1.8 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Aehr Test Systems, Inc. have too much debt?
No — Aehr Test Systems, Inc.'s debt-to-equity is 0.05. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.
What is Aehr Test Systems, Inc.'s capex?
Aehr Test Systems, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is Aehr Test Systems, Inc.'s cash flow?
Aehr Test Systems, Inc. consumed $0.0 B of operating cash in FY25 — cash flowed out rather than in (free cash flow: $−0.0 B). Reported profit that year was $0.0 B, so operating cash ran behind profit. — as of 17 September 2026.
Is Aehr Test Systems, Inc.'s profit real cash?
Not fully — over the last 3 fiscal years, 20% of Aehr Test Systems, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $−0.0 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Aehr Test Systems, Inc.?
On the balance sheet, the Z-score reads 23.98 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Aehr Test Systems, Inc. in its business cycle?
Aehr Test Systems, Inc.'s FY25 operating margin was −16.7%, against a 5-year band of −16.7%–20.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 0.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Aehr Test Systems, Inc. story?
The sharpest disagreement: the price moved +181.3% in a year while annual EPS moved −111.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Aehr Test Systems, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Aehr Test Systems, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!